Machine Learning Engineers, Isomorphic Labs
NeurIPS 2025 Interviews
More information about location
3 days a week in office
AI-driven drug discovery and development
Posted today
AI-driven drug discovery and development
201-500 employees
Posted today
More information about location
3 days a week in office
201-500 employees
Company mission
To use AI and machine learning methods to accelerate and improve the drug discovery process.
Role
Who you are
- Deep experience with developing large-scale machine learning models
- Significant experience with solving real-life challenges with ML models and techniques
- Experience with modern ML frameworks including at least one of JAX, PyTorch or TensorFlow
- Experience with the full ML research and development lifecycle
- Experience partnering with research and product teams to prototype and ideally productionise ML models
- Strong software engineering experience with software design / architecture skills
- Extensive programming experience using any mainstream programming languages, including strong Python experience
- Strong understanding of ML theory and applications
- Strong understanding of data structures and algorithms
- Either a Bachelor’s degree in Computer Science, a related technical field, or equivalent practical experience
Desirable
- Interest in chemistry and biology
- Experience working with biomedical data
- Knowledge of the pharmaceutical industry, ideally with a focus on drug discovery
- Experience developing user facing production code
What the job involves
- We’ll be at NeurIPS 2025 in San Diego conducting in-person interviews with exceptional Machine Learning Engineers at all levels to join our teams in London and Lausanne
- Partner with the ML Research, Drug Design, and Data Engineering teams to design, develop, train, and evaluate a variety of cutting edge ML models at unprecedented scale
- Apply the state-of-the-art ML models and techniques to real-life drug discovery challenges
- Build a world-class ML drug design research environment with scalable software and libraries
- Create novel instrumental drug discovery tools in partnership with domain experts. Take end-to-end ownership from rapid prototyping to production-quality code
- Iterate collaboratively with scientists and domain experts to deeply understand feature requirements and user feedback
- Develop tools and libraries to enable large-scale machine learning experiments across thousands of accelerators
- Maximise model performance, scalability, and robustness for production use within our computational platform
Application process
- We’ll be at NeurIPS 2025 in San Diego conducting in-person interviews with exceptional Machine Learning Engineers at all levels to join our teams in London and Lausanne
- For candidates who successfully pass our screening process, we will be conducting in-person interviews in San Diego on 2nd and 3rd Dec, during NeurIPS conference
Salary benchmarks
Our take
The discovery of new drugs is essential for medical innovations, but the process is lengthy, high-risk, and expensive. This is due to manual research and analysis processes that are prone to human error and time-consuming workflows, raising the question as to whether AI could reduce these pitfalls.
Rather than bolting machine learning onto the existing drug discovery process, Isomorphic Labs is reimagining everything from first principles with an AI-first approach, leveraging machine learning to build predictive and generative models of biological phenomena to understand how novel drugs could perform. And the company differentiates itself from other AI-driven drug discovery startups by being a direct subsidiary of Alphabet, with access to resources, computing power, and partnerships with teams within DeepMind.
Now, the company is gearing up for its biggest leap yet - testing its AI-designed medicines on real people. After years of development, big-name partnerships, and a $600M funding round, Isomorphic says human clinical trials are finally within reach. In its London offices, scientists and AI are already teaming up to design potential treatments for diseases like cancer. The next step is putting those drugs to the test.
Kirsty
Company Specialist at Welcome to the Jungle
Insights
30% female employees
Company
Funding (1 round)
Mar 2025
$600m
LATE VC
Total funding: $600m
Company benefits
- Hybrid working: It’s hugely important for us to share knowledge and build strong relationships with each other, and we find it easier to do this if we spend time together in person. This is why we follow a hybrid model, and would require you to be able to come into the office 3 days a week (currently Tuesday, Wednesday, and one other day depending on which team you’re in). If you have additional needs that would prevent you from following this hybrid approach, we’d be happy to talk through these if you’re selected for an initial screening call
Company values
- Thoughtful: Thoughtful at Iso is about curiosity, creativity and care. It is about good people doing good, rigorous and future-making science every single day
- Brave: Brave at Iso is about fearlessness, but it’s also about initiative and integrity. The scale of the challenge demands nothing less
- Determined: Determined at Iso is the way we pursue our goal. It’s a confidence in our hypothesis, as well as the urgency and agility needed to deliver on it. Because disease won’t wait, so neither should we
- Together: Together at Iso is about connection, collaboration across fields and catalytic relationships. It’s knowing that transformation is a group project, and remembering that what we’re doing will have a real impact on real people everywhere
Company HQ
London, UK
Articles
Leadership
Demis Hassabis
(Co-Founer & CEO)Co-founded Google DeepMind in 2010 and has served as the CEo ever since.
Share this job
View 10 more jobs at Isomorphic Labs